GlassScriptPhysician profile
Nadeen Ajami
NPI 1538845078
$1,212.15
in general payments reported to CMS, 2019-2025
17 companies · $476 in 2025
The $476 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $273 · 2024: $463 · 2025: $476.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,212.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $244.27 | 2023-2025 | Minimed 780g |
| Novo Nordisk INC | $204.27 | 2024-2025 | Ozempic, Sogroya |
| Amgen INC. | $183.31 | 2024 | Tepezza |
| Boston Scientific Corporation | $144.86 | 2023-2024 | Bodyguardian |
| Revance Therapeutics, INC. | $133.33 | 2025 | Daxxify |
| Lilly USA, LLC | $62.01 | 2024-2025 | Jardiance, Mounjaro |
| Pfizer INC. | $34.97 | 2024-2025 | |
| Galderma Laboratories, L.P. | $33.11 | 2025 | |
| Amneal Pharmaceuticals LLC | $32.90 | 2023-2024 | Unithroid |
| Corcept Therapeutics | $22.33 | 2024 | Korlym |
| Amphastar Pharmaceuticals, INC. | $21.74 | 2025 | |
| Astellas Pharma US INC | $20.33 | 2023 | Veozah |
| Tolmar, INC. | $19.85 | 2024 | |
| Recordati_rare_diseases_inc. | $18.11 | 2024 | Signifor Lar, Isturisa |
| Chiesi USA, INC. | $15.33 | 2024 | Mycapssa |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $15.00 | 2024 | Nexletol |
| Theracosbio, LLC | $6.43 | 2024 | Brenzavvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nadeen Ajami listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.